ACTINIUM PHARMACEUTICALS INC (ATNM)

US00507W2061 - Common Stock

1.44  +0.18 (+14.29%)

After market: 1.37 -0.07 (-4.86%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
1.144M1.03M
-9.97%
81K
-92.14%
231.744K
186.10%
44.84M
19,248.94%
90.576M
102.00%
17.986M
-80.14%
47.252M
162.72%
145.03M
206.93%
182.29M
25.69%
253.97M
39.32%
EBITDA
YoY % growth
-24.44M
-11.36%
-33.405M
-36.68%
-51.13M
-53.06%
-49.572M
3.05%
-50.592M
-2.06%
-53.142M
-5.04%
-60.486M
-13.82%
-68.952M
-14.00%
N/AN/AN/A
EBIT
YoY % growth
-24.964M
-11.48%
-34.104M
-36.61%
-51.92M
-52.24%
-47.784M
7.97%
-43.81M
8.32%
-49.793M
-13.66%
-48.82M
1.95%
-35.24M
27.82%
41.952M
219.05%
58.3M
38.97%
106.91M
83.38%
Operating Margin
-2,182.17%-3,311.07%-64,098.77%-20,619.28%-97.70%-54.97%-271.43%-74.58%28.93%31.98%42.10%
EPS
YoY % growth
-1.20
41.18%
-1.37
-14.17%
-1.84
-34.31%
-1.36
26.16%
-0.71
47.96%
-1.19
-68.07%
-1.07
10.15%
-0.96
10.19%
-0.18
81.38%
0.46
360.00%
1.22
163.74%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25 Q1 / 26 Q2 / 26 Q3 / 26
EPS
Q2Q % growth
-0.39
-14.75%
-0.60
-94.13%
-0.57
-50.32%
-0.53
-43.35%
-0.49
-25.49%
-0.58
3.39%
-0.54
5.36%
-0.49
7.69%
Revenue
Q2Q % growth

-100.00%
1.52M3.041M4.63M6.22M8.429M
454.54%
10.145M
233.61%
11.861M
156.18%
EBITDA
Q2Q % growth
-14.28M
-49.48%
N/AN/AN/AN/AN/AN/AN/A
EBIT
Q2Q % growth
-12.542M
-21.26%
N/AN/AN/AN/AN/AN/AN/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
-0.37
24.49%
-0.34-0.03-7.96%
Q2 2024
Q2Q % growth
-0.38
34.48%
-0.410.038.01%
Q1 2024
Q2Q % growth
-0.31
27.91%
-0.530.2241.55%
Q4 2023
Q2Q % growth
-0.34
20.93%
-0.550.2138.27%
Q3 2023
Q2Q % growth
-0.49
-28.95%
-0.540.059.64%
Q2 2023
Q2Q % growth
-0.58
-75.76%
-0.49-0.09-18.46%
Q1 2023
Q2Q % growth
-0.43
-86.96%
-0.430.000.42%
Q4 2022
Q2Q % growth
-0.43
-19.44%
-0.36-0.07-18.75%
Q3 2022
Q2Q % growth
-0.38
-26.67%
-0.31-0.07-22.15%
Q2 2022
Q2Q % growth
-0.33
-32.00%
0.52-0.85-164.07%
Q1 2022
Q2Q % growth
-0.23
20.69%
-0.320.0928.42%
Q4 2021
Q2Q % growth
-0.36
2.70%
-0.31-0.05-15.72%
Q3 2021
Q2Q % growth
-0.30
16.67%
-0.28-0.02-5.80%
Q2 2021
Q2Q % growth
-0.25
39.02%
-0.300.0517.61%
Q1 2021
Q2Q % growth
-0.29
67.78%
-0.300.013.07%
Q4 2020
Q2Q % growth
-0.37
58.89%
-0.380.011.96%
Q3 2020
Q2Q % growth
-0.36
70.00%
-0.450.0920.24%
Q2 2020
Q2Q % growth
-0.41
54.44%
-0.410.00-0.52%
Q1 2020
Q2Q % growth
-0.90
40.00%
-0.71-0.19-26.07%
Q4 2019
Q2Q % growth
-0.90 -1.220.3226.47%
Q3 2019
Q2Q % growth
-1.20 -1.12-0.08-6.94%
Q2 2019
Q2Q % growth
-0.90 -1.220.3226.47%
Q1 2019
Q2Q % growth
-1.50 -1.730.2313.50%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth

-100.00%
586.5K-586.5K-100.00%
Q2 2023
Q2Q % growth

-100.00%
%
Q1 2023
Q2Q % growth

-100.00%
%
Q4 2022
Q2Q % growth

-100.00%
1.055M-1.055M-100.00%
Q3 2022
Q2Q % growth
45K
-80.69%
500.647K-455.647K-91.01%
Q2 2022
Q2Q % growth
45K
-83.08%
17.85M-17.805M-99.75%
Q1 2022
Q2Q % growth
940K
51.13%
940K%
Q4 2021
Q2Q % growth
23K 81.6K-58.6K-71.81%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% 21.94% 0% -1.06%
RevenueN/A N/A 0% 0%